Lallemand Pharma

What Lallemand Pharma does

Lallemand Pharma AG is the pharmaceutical subsidiary of privately held Canadian parent Lallemand Inc. (founded 1890), operating from Massagno, Switzerland, with regional operations in Grenaa, Denmark, and a core team of approximately 6 employees per firmographic records. The company focuses exclusively on respiratory products, commercializing two technology platforms through a B2B licensing and distribution model. The first platform is PMBL (Polyvalent Mechanical Bacterial Lysate), an in-house-produced immunostimulant sublingual tablet using a proprietary mechanical lysis process that preserves antigen integrity; PMBL drugs have been marketed since 2007 under the brands Ismigen, Immubron, Respibron, and PIR-05 for prevention and treatment of recurrent respiratory tract infections. The second platform is Symbiofilm, an exopolymeric ingredient derived from fermentation of a proprietary extremophilic marine bacterium (Bacillus licheniformis T14) with a documented triple-action mechanism: antibiofilm activity, antiviral adhesion protection, and a film-forming barrier, marketed via the Healsea line of nasal spray medical devices (Babykids, Children, Rescue, Chronic variants) introduced from 2018. Manufacturing is conducted in a single GMP-pharma certified plant under ISO 13485 with CE marking obtained in April 2021 and MDR certification achieved in March 2025 for the pump spray product line.

Lallemand Pharma serves two principal customer segments. The primary indirect end users are patients with recurrent respiratory tract infections (for PMBL drugs, prescription-based) and patients with nasal and sino-nasal conditions including allergic rhinitis, chronic sinusitis, and acute infectious rhinitis (for Healsea medical devices). The direct customers are pharmaceutical distribution and licensing partners — regional pharma companies that hold territory rights, handle local regulatory compliance, and conduct marketing and sales within their markets; named partners include Merck (Latin America), STADA CIS (Russia), Zambon (Italy), GM PHARMA (Georgia), and Avalon Pharma (Saudi Arabia). Revenue mechanics are based on pharmaceutical product supply and licensing arrangements (one-time license style commercial terms), with pricing not publicly disclosed and business development handled through the [email protected] channel. The go-to-market is partner-driven channel/distributor motion with supplementary healthcare professional engagement via scientific conferences (ERS, EAACI, WCP, PharmaSynergy OTC), CME events, and a publications database accessible through a Partner Area on the corporate website.

The competitive position rests on proprietary manufacturing know-how held as trade secrets rather than patents, a defensible regulatory stack (GMP, CE, MDR, ISO 13485), clinical evidence generated through studies such as AIACE (288 patients, COPD) and EOLIA, and a portfolio of differentiated SKUs that span both prescription immunostimulant and OTC-style nasal device categories. Active commercial expansion has continued through 2024–2025 with new partner launches in Saudi Arabia (July 2024) and Georgia (January 2025), underwritten by the March 2025 MDR certification that supports broader EU-wide commercialization of the pump spray line with upgraded indications.

Name

Lallemand Pharma

Legal name

Lallemand Inc.

Website

https://lallemandpharma.com

Company type

Private

Founded year

1890

Operating status

Operating

Headcount range

1–10 employees

Short description

Lallemand Pharma AG is a Swiss pharmaceutical subsidiary of Canada's Lallemand Inc. that develops and licenses respiratory products — PMBL immunostimulant drugs (Ismigen, Immubron, Respibron, PIR-05) and Symbiofilm-based Healsea nasal spray medical devices — to regional pharmaceutical distribution partners across Europe, the Middle East, Latin America, and the CIS.

Ownership category

akta.pro rank

Product category

Respiratory Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAIACAF

Pulmonology & Allergy Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAHAIAK

Nasal Drug Delivery Devices (Sprays/Powder Devices)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

SECONDARYHLAIADAC

Allergy, Sinus & Respiratory (Non-Asthma)

Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

SECONDARYHLAIAAAH

Respiratory & Allergy Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Respiratory pharmaceuticals
• Bacterial lysate therapy
• Nasal spray devices
• Immunostimulant drugs
• Marine biotechnology ingredients

Headquarters

HQ city

Massagno

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Others

Revenue model

1. PMBL Drug Sales: Sale of prescription drugs containing PMBL (Polyvalent Mechanical Bacterial Lysate) as active ingredient, marketed under brands including Ismigen, Immubron, Respibron, and PIR-05. Indicated for prevention and treatment of recurrent respiratory tract infections.
2. Healsea Medical Device Sales: Sale of nasal spray medical devices containing Symbiofilm, including Healsea Babykids, Healsea Rescue, Healsea Children, and Healsea Chronic products. Available in bag on valve technology and manual spray pump formats.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Lallemand Pharma develops, manufactures, and commercializes two main lines of respiratory health products: (1) PMBL (Polyvalent Mechanical Bacterial Lysate) sublingual immunostimulant tablets marketed under regional brands including Ismigen, Immubron, Respibron, and PIR-05 for prevention and treatment of recurrent respiratory tract infections, and (2) Healsea nasal spray medical devices containing the proprietary Symbiofilm ingredient for nasal care in acute infectious rhinitis, allergic rhinitis, and chronic sinusitis. The company holds MDR certification, CE marking, and ISO 13485, and outsources local commercialization through pharmaceutical licensing partners across multiple territories.

Product overview

Lallemand Pharma offers a portfolio of respiratory health products consisting of two main categories: prescription drugs (PMBL® sublingual tablets) containing bacterial lysate for immunostimulation, and medical devices (Healsea® nasal spray line) containing Symbiofilm® for mechanical nasal care. The PMBL® products are marketed under multiple brand names (Ismigen®, Immubron®, Respibron®, PIR-05®) for prevention and treatment of recurrent respiratory tract infections. The Healsea® line includes four formulations (Babykids, Children, Rescue, Chronic) differentiated by concentration of Symbiofilm®, salt solution type (isotonic/hypertonic), delivery technology (pump spray/Bag on Valve), and target age group. Additional products include Salinose® Bagonvalve marketed through the Saudi Arabia partnership.

Differentiator

Problem solved

Functional benefit

Brands

• PMBL: Polyvalent Mechanical Bacterial Lysate - the company's proprietary active ingredient for sublingual tablet drugs indicated in prevention of recurrent respiratory tract infections.
• Symbiofilm
• Healsea
• Healsea Babykids
• Healsea Rescue
• Healsea Children
• Healsea Chronic
• Salinose

Products and services

• PMBL® (Polyvalent Mechanical Bacterial Lysate) Immunostimulant sublingual tablets containing bacterial lysate obtained by mechanical lysis, indicated for the prevention and treatment of recurrent respiratory tract infections. Marketed under regional brand names (Ismigen®, Immubron®, Respibron®, PIR-05®) by local pharmaceutical partners.
• Healsea® Babykids 100% natural isotonic nasal spray for children from 2 years old, containing isotonic saline solution and Symbiofilm®. Indicated for treatment of symptoms of acute infectious rhinitis such as colds and flu. Drug-free, preservative-free, 20ml pump spray with APF technology, MDR approved.
• Healsea® Children 100% natural isotonic nasal spray with seawater and Symbiofilm® for children above 6 years. 100ml aerosol with Bag on Valve (BoV) technology for cleaning and moistening the nose during colds and rhinitis. MDD approved.
• Healsea® Rescue 100% natural hypertonic nasal spray for adults from 18 years, containing hypertonic saline solution and Symbiofilm®. Indicated for treatment of symptoms of acute infectious rhinitis such as colds and flu.
• Healsea® Chronic 100% natural hypertonic nasal spray for adults, containing hypertonic seawater and Symbiofilm®. Indicated for treatment of nasal symptoms of chronic sino-nasal conditions including allergic rhinitis, chronic sinusitis, and sensitive nose, and as post-operative nasal care. Available in 50ml and 150ml sizes. MDD approved.
• Symbiofilm® Exopolymeric ingredient derived from proprietary marine bacteria (Bacillus licheniformis T14). An extremophilic compound that slows down turnover of pathogenic bacteria biofilm, reduces attachment of respiratory viruses on nasal mucosa, and creates a protective film barrier. Subject of lyophilization after fermentation and filtration.
• Salinose® Bagonvalve Nasal irrigation product introduced through partnership with Avalon Pharma in Saudi Arabia, offering precise and effective nasal irrigation with Symbiofilm® ingredient that inhibits biofilm formation and viral adhesion.

Quantifiable outcome

• Reduction in number of days of hospitalization for COPD patients when PMBL used as add-on therapy (AIACE study - 288 patients)
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and major.

• GM PHARMA (GM Pharmaceuticals LTD)coreChannel Partner/ Reseller/ Distributor · 15 January 2025Partnership for launch of Healsea nasal spray in Georgia. GM PHARMA is already a long-standing partner for PMBL products. The partnership leverages GM PHARMA's expertise in licensing and distributing pharmaceutical products for successful market entry of Healsea in Georgia.
• Avalon PharmacoreChannel Partner/ Reseller/ Distributor · 16 July 2024Strategic partnership with Avalon Pharma, a dynamic Saudi pharmaceutical firm, to enhance respiratory healthcare in Saudi Arabia. Introduction of Salinose Bagonvalve technology with Symbiofilm ingredient for nasal irrigation. Both teams worked tirelessly across various departments to achieve this significant milestone for improved healthcare outcomes in Saudi Arabia.
• MerckcoreChannel Partner/ Reseller/ Distributor · 19 November 2014Marketing partnership for ISMIGEN in Latin America. Spurred by success of ISMIGEN in Latin America, partnership continued for expanded marketing efforts across the region.
• STADA CIScoreChannel Partner/ Reseller/ Distributor · 13 November 2014Partnership for launch of PMBL tablets (Ismigen) in Russian market - an immunomodulating product for respiratory infections.
• ZambonmajorChannel Partner/ Reseller/ DistributorItalian partner organizing CME events about prophylaxis and treatment of respiratory infections with Lallemand Pharma experts including Pr G.Di Perri and Pr G.Ferlazzo.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Angelini Pharma: Italian privately-held specialty pharma with respiratory and CNS focus. Comparable as a mid-sized European specialty pharma using licensing/distribution partnerships across multiple territories, with overlapping presence in respiratory indications and OTC consumer health adjacencies.
• Zambon: Italian specialty pharmaceutical company with a strong respiratory portfolio and existing partnership with Lallemand Pharma in Italy. Comparable as a mid-sized European respiratory pharma operating across multiple brands and distribution channels, with overlapping therapeutic focus in respiratory infections and COPD.
• NeilMed Pharmaceuticals: US-based manufacturer of nasal saline irrigation products (Sinus Rinse, NeilMed) sold globally. Direct competitor in the nasal saline/medical device category, comparable in product positioning (drug-free nasal care for sinusitis/allergic rhinitis) and over-the-counter retail distribution model.
• OM Pharma: Swiss specialty pharma company (a subsidiary of Abionyx Pharma) that markets Broncho-Vaxom, the leading bacterial lysate immunostimulant for respiratory infections. Directly competes with Lallemand Pharma's PMBL/Ismigen franchise in the same therapeutic category using a similar bacterial lysate mechanism.
• Laboratoire de la Mer (Physiomer): French manufacturer of the Physiomer seawater nasal spray range, a leading European nasal saline brand. Directly comparable in product category (multi-SKU nasal spray line for children/adults, isotonic and hypertonic variants) and target use cases (colds, allergic rhinitis, sinusitis).

Broad incumbents

• Recordati: Italian specialty pharma group listed on the Italian Stock Exchange, with respiratory and rare disease franchises. Comparable European specialty pharma footprint with similar licensing-based expansion into multiple regions, though operating at much larger scale.
• Church & Dwight (Sterimar): US-listed consumer health company owning the Sterimar nasal saline brand, a direct competitor to Lallemand's Healsea nasal spray line in the OTC nasal care category. Comparable in product category (isotonic/hypertonic seawater nasal sprays) and target consumer segments, but with vastly larger marketing resources.
• STADA Arzneimittel: German generics and specialty pharma company, already a partner of Lallemand Pharma (STADA CIS for Russia). Comparable as a European specialty pharma using licensing/distribution for portfolio expansion, with respiratory generics and consumer health OTC products.
• Chiesi Farmaceutici: Large privately-held Italian pharmaceutical company with a significant respiratory franchise (Foster, Trimbow, NEXThaler). While much larger and broader than Lallemand Pharma, it competes in the same pulmonology/respiratory specialty space across Europe with similar HCP-targeted go-to-market.
• Merck KGaA (Consumer Health): German science and technology company with consumer health portfolio, already a Lallemand Pharma partner for Ismigen in Latin America. Comparable in distribution partnership dynamics and respiratory/OTC consumer health market presence, though operating at vastly larger scale across multiple therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCk6vgO2igO7JkPTK7RWlhAA
• LinkedInlinkedin.com/company/lallemand-pharma

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lallemand Pharma